TABLE 3.
Bacteriologic response at the end of treatment and at follow-up in microbiologically evaluable patients treated with grepafloxacin (400 or 600 mg once daily) or ciprofloxacin (500 mg twice daily)
| Time and response | Grepafloxacin at 400 mg once daily | Grepafloxacin at 600 mg once daily | Ciprofloxacin at 500 mg twice daily |
|---|---|---|---|
| End-of-treatment | |||
| Total no. of evaluable pathogens | 96 | 89 | 90 |
| Success (no. [%] of patients) | 92 (96) | 87 (98) | 82 (92) |
| Eradication | 11 (12) | 17 (19) | 9 (10) |
| Presumed eradication | 77 (80) | 68 (76) | 73 (81) |
| Eradication + contamination or colonization | 4 (4) | 2 (2) | 0 |
| Reinfection | 0 | 0 | 0 |
| Failure (no. [%] of patients) | 4 (4) | 2 (2) | 8 (9) |
| Presumed persistence | 3 (3) | 2 (2) | 3 (3) |
| Persistence | 0 | 0 | 1 (1) |
| Relapse | 1 (1) | 0 | 4 (4) |
| Follow-up | |||
| Total no. of evaluable pathogens | 95 | 89 | 84 |
| Success (no. [%] of patients) | 82 (86) | 78 (88) | 69 (82) |
| Eradication | 4 (4) | 12 (14) | 2 (2) |
| Presumed eradication | 74 (78) | 62 (70) | 63 (75) |
| Eradication + contamination or colonization | 4 (4) | 4 (5) | 1 (1) |
| Reinfection | 0 | 0 | 3 (4) |
| Failure (no. [%] of patients) | 13 (14) | 11 (12) | 15 (18) |
| Presumed persistence | 10 (11) | 6 (7) | 11 (13) |
| Persistence | 1 (1) | 0 | 0 |
| Relapse | 2 (2) | 5 (6) | 4 (5) |